Thursday, 29 October 2026 Every NSE & BSE announcement, by company
ALFA Filings Every announcement, straight from the exchange
Acquisition

Marksans Pharma Acquisition Worth ₹71.25 Cr

Marksans Pharma is acquiring 100% of Netherlands-based QliniQ B.V. for ₹71.25 Crore. The deal strengthens Marksans' European distribution and forward-integration strategy.

Key figures
Value₹71.25 Cr
Execution periodExpected completion by June 15, 2026
Source

BSE filing, NSE: MARKSANS. Summary written from the filing by ALFA Finder's alert engine.

Read the filing ↗

Marksans Pharma Ltd: key numbers

Share price
₹305.20
Market cap
₹13,831 Cr
Revenue (annual)
₹2,951 Cr
Net profit (annual)
₹417.9 Cr
P/E (TTM)
26.8×Sector 46.1×
Promoter holding
43.87%+0.00% QoQ
FII holding
19.06%Current quarter

Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.

More from Marksans Pharma Ltd

All →

Other acquisition announcements

All →